2.3.2. Exclusion criteria.
hepatitis B, arrhythmia, immunodeficiency diseases, infections, tuberculosis, infertility, malignant tumors, blood abnormalities, hepatic dysfunction, heart failure, antiphospholipid antibody syndrome, hypersensitivity, blood coagulation
HEPATITIS B, COLLAGEN VASCULAR DISEASES, VIRUS, UNCONTROLLED HYPERTENSION, RENAL IMPAIRMENT, ISCHEMIC HEART DISEASE, ARRHYTHMIA, INFECTIONS, TUBERCULOSIS, FUNGAL INFECTIONS, MALIGNANT TUMORS, HEPATITIS C, IMMUNODEFICIENCY DISEASE, CHRONIC ENDOMETRITIS, HEART FAILURE, ANTIPHOSPHOLIPID ANTIBODY SYNDROME, HYPERSENSITIVITY
Patients who used immunosuppressive drugs for infertility treatment, such as tacrolimus, azathioprine, mizoribine, mycophenolate mofetil, cyclophosphamide, gusperimus, everolimus, ciclosporin, basiliximab, infliximab, etanercept, golimumab, tocilizumab, canakinumab, rituximab, abatacept, corticosteroids, and intravenous immunoglobulinPatients diagnosed with chronic endometritis by endometrial histologyPatients infected with human immunodeficiency virus, hepatitis C virus, hepatitis B virus, or other active viruses; Patients under treatment or previously treated for infections caused by tuberculosis or invasive fungal infections; and those who are undergoing treatment for other bacterial infectionsPatients with poorly controlled hypertension under antihypertensive drug treatment: systolic blood pressure ≥ 140 mm Hg/diastolic blood pressure ≥ 90 mm HgPatients with renal impairment: estimated glomerular filtration rate < 60 mL/min/1.73 mPatients with severe hepatic dysfunction: aspartate transaminase or alanine transaminase ≥2.5 times the upper reference limit for each facilityPatients with heart failure, ischemic heart disease, or serious arrhythmia and those with a history of these disordersPatients with immunodeficiency diseases and those with a history of themPatients with malignant tumors (including suspected patients) or a history of malignant tumorsPatients with a history of organ transplantationPatients with a history of hypersensitivity to tacrolimusPatients with the following blood abnormalities: white blood cell count < 2000/μL, neutrophil count < 1500/μL, and platelet count < 50,000/μLPatients who participated in other interventional clinical trials within 6 months of registration or who plan to participate in other interventional clinical trials during this study periodPatients with untreated endocrine dysfunctionsPatients with blood coagulation abnormalitiesPatients with antiphospholipid antibody syndrome and collagen vascular diseases associated with infertility or recurrent pregnancy lossPatients or their partners with chromosomal aberrationsPatients receiving bosentanPatients receiving potassium-sparing diureticsPatients who receive live vaccines 2 months prior to the registrationPatients with other conditions that the principal investigator or sub-investigator deems ineligible